Analysts See $-0.38 EPS for Kindred Biosciences, Inc. (KIN)

April 26, 2018 - By Vivian Park

Kindred Biosciences, Inc. (NASDAQ:KIN) LogoInvestors sentiment decreased to 0.93 in 2017 Q4. Its down 1.31, from 2.24 in 2017Q3. It dived, as 12 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 8 funds opened positions while 18 raised stakes. 17.44 million shares or 4.61% less from 18.28 million shares in 2017Q3 were reported.
Ameritas Ptnrs Incorporated holds 0% or 1,848 shares. C M Bidwell & Associate invested 0.21% in Kindred Biosciences, Inc. (NASDAQ:KIN). Legal General Group Public Limited Company holds 0% or 4,693 shares in its portfolio. 11,383 were reported by Voya Investment Limited Company. Mufg Americas Corporation has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). 40 are held by Commercial Bank Of Montreal Can. Millennium Ltd Liability Company has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Bridgeway Mngmt holds 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 13,900 shares. Vanguard holds 1.02M shares or 0% of its portfolio. Ariel Invests Lc invested in 1.96 million shares. Jpmorgan Chase And Co invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Manufacturers Life Insur Company The accumulated 22,105 shares. State Street Corporation, a Massachusetts-based fund reported 344,019 shares. Dimensional Fund Lp invested in 0.01% or 1.36M shares. California State Teachers Retirement Sys accumulated 39,869 shares.

Since January 2, 2018, it had 0 buys, and 4 insider sales for $254,552 activity. 6,419 Kindred Biosciences, Inc. (NASDAQ:KIN) shares with value of $60,660 were sold by Townsend Raymond.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.38 EPS on May, 2.They anticipate $0.08 EPS change or 26.67 % from last quarter’s $-0.3 EPS. After having $-0.35 EPS previously, Kindred Biosciences, Inc.’s analysts see 8.57 % EPS growth. The stock decreased 2.21% or $0.2 during the last trading session, reaching $8.85. About 99,908 shares traded or 15.02% up from the average. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 18.31% since April 26, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 3 analysts covering Kindred Biosciences (NASDAQ:KIN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Kindred Biosciences had 5 analyst reports since November 17, 2017 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Friday, March 2. The rating was initiated by C.L. King with “Hold” on Wednesday, December 27. The firm has “Buy” rating given on Monday, February 26 by FBR Capital.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $249.47 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.